Search details
1.
Prescribing Syringes to People Who Inject Drugs: Advancing Harm Reduction in Primary Care.
J Gen Intern Med
; 38(8): 1980-1983, 2023 06.
Article
in English
| MEDLINE | ID: mdl-37020124
2.
Reducing the harms of xylazine: clinical approaches, research deficits, and public health context.
Harm Reduct J
; 20(1): 141, 2023 09 30.
Article
in English
| MEDLINE | ID: mdl-37777769
3.
Research Priorities for Expansion of Opioid Use Disorder Treatment in the Community Pharmacy.
Subst Abus
; 44(4): 264-276, 2023 10.
Article
in English
| MEDLINE | ID: mdl-37902032
4.
Independent community pharmacists' attitudes and intentions toward dispensing buprenorphine/naloxone for opioid use disorder.
J Am Pharm Assoc (2003)
; 63(5): 1558-1565.e4, 2023.
Article
in English
| MEDLINE | ID: mdl-37331654
5.
The impact of the mainstreaming addiction treatment act and associated legislative action on pharmacy practice.
J Am Pharm Assoc (2003)
; 63(4): 1039-1043, 2023.
Article
in English
| MEDLINE | ID: mdl-37088366
6.
A wound care and immunization needs assessment for participants of a mobile syringe services program in Austin, TX.
J Am Pharm Assoc (2003)
; 63(1): 361-365.e1, 2023.
Article
in English
| MEDLINE | ID: mdl-36549930
7.
A qualitative exploration of unintentional versus intentional exposure to fentanyl among people who use drugs in Austin, TX.
J Am Pharm Assoc (2003)
; 63(1): 317-323, 2023.
Article
in English
| MEDLINE | ID: mdl-36503811
8.
Perceptions, policies, and practices related to dispensing buprenorphine for opioid use disorder: A national survey of community-based pharmacists.
J Am Pharm Assoc (2003)
; 63(1): 252-260.e6, 2023.
Article
in English
| MEDLINE | ID: mdl-36202711
9.
Opioid harm reduction: A scoping review of physician and system-level gaps in knowledge, education, and practice.
Subst Abus
; 43(1): 972-987, 2022.
Article
in English
| MEDLINE | ID: mdl-35426772
10.
Policies regarding use of medications for opioid use disorder in professional recovery programs: A scoping review.
Subst Abus
; 43(1): 749-755, 2022.
Article
in English
| MEDLINE | ID: mdl-35100089
11.
Naloxone accessibility without an outside prescription from U.S. community pharmacies: A systematic review.
J Am Pharm Assoc (2003)
; 62(6): 1725-1740, 2022.
Article
in English
| MEDLINE | ID: mdl-35989151
12.
Impact of student pharmacist-led naloxone academic detailing at community pharmacies in Texas.
J Am Pharm Assoc (2003)
; 60(1): 81-86, 2020.
Article
in English
| MEDLINE | ID: mdl-31669417
13.
Pharmacists are missing an opportunity to save lives and advance the profession by embracing opioid harm reduction.
J Am Pharm Assoc (2003)
; 59(6): 779-782, 2019.
Article
in English
| MEDLINE | ID: mdl-31402146
14.
Correction: Reducing the harms of xylazine: clinical approaches, research deficits, and public health context.
Harm Reduct J
; 20(1): 170, 2023 Nov 27.
Article
in English
| MEDLINE | ID: mdl-38012764
15.
Reply.
J Am Pharm Assoc (2003)
; 60(5): e22-e23, 2020.
Article
in English
| MEDLINE | ID: mdl-32222528
16.
Relationships Between Stigma, Risk Tolerance, and Buprenorphine Dispensing Intentions Among Community-Based Pharmacists: Results From a National Sample.
Subst Use Addctn J
; 45(2): 211-221, 2024 Apr.
Article
in English
| MEDLINE | ID: mdl-38258805
17.
Protocol for the development of a consensus practice guideline To address clinical and regulatory barriers to buprenorphine dispensing in community pharmacy.
Arch Public Health
; 82(1): 58, 2024 Apr 25.
Article
in English
| MEDLINE | ID: mdl-38664777
18.
Naloxone Accessibility Without a Prescriber Encounter Under Standing Orders at Community Pharmacy Chains in Texas.
JAMA
; 320(18): 1934-1937, 2018 11 13.
Article
in English
| MEDLINE | ID: mdl-30422186
19.
Description and Evaluation of a Pilot Advanced Pharmacy Practice Experience in Addiction Medicine.
Am J Pharm Educ
; 87(1): ajpe8926, 2023 01.
Article
in English
| MEDLINE | ID: mdl-35131764
20.
Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in 11 U.S. states.
Drug Alcohol Depend
; 237: 109518, 2022 08 01.
Article
in English
| MEDLINE | ID: mdl-35691255